KetoTV reported on Thursday that Nicolas Tzenios plans to launch a keto clinical trial under a partnership with KGK Science Inc, a contract research organisation.
Hon Prof Dr Nicolas Tzenios is the chairman of medical research hub TRCGEN+. He is the author of 'Nic's Keto Diet', a book which is now available in four languages, and created a Keto postgraduate course that is taught in universities and colleges across the globe. TRCGEN+ sponsors medical research clinical trials including Keto diet effects and a genetic research related to specific genetic cancer treatment approach with Kursk State Medical University.
Through this research programme, Hon Prof Tzenios hopes to prove his 'Friendly LDL Theory', which suggests that in the absence of elevated glucose, low-density lipoprotein (LDL) does not oxidise or form plaque and has anti-inflammatory effects. He believes that elevated glucose, rather than fat, results in the onset of cardiovascular and diet-related diseases.
In addition, Hon Prof Tzenios is applying to patent his Friendly LDL Theory. This concept is inspired by the success of the keto diet, which involves the ingestion of high-fat, low-carb foods. If corroborated, his theory has the potential to greatly impact the realm of dietary science, KetoTV said.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Halia Therapeutics collaborates with Canary Speech
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007
Sanofi reports FDA approval for Dupixent in paediatric EoE treatment